Explore /
Poster
/ Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).

Authors

Arpit Rao

Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX

Arpit Rao , Glenn Heller , Charles J. Ryan , David James VanderWeele , Lionel D Lewis , Alan Tan , Colleen Watt , Ronald C. Chen , Manish Kohli , Pedro C. Barata , Benjamin Adam Gartrell , Robert Grubb , Amylou C. Dueck , Yujia Wen , Michael J. Morris

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT04455750

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS5107)

DOI

10.1200/JCO.2022.40.16_suppl.TPS5107

Abstract #

TPS5107

Poster Bd #

283a

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Genitourinary Cancers Symposium